ZBTB33 and chronic myelogenous leukemia, BCR-ABL1 positive: Being a more advanced phase of CML and has a poor prognosis for the patient, since some of them are resistant to imatinib therapy [3,7], it seemed appropriate to begin to characterize these cells.Immunofluorescence analysis showed the cytoplasmic distribution/accumulation of Kaiso in K562 cell line (Figure1A).